Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

6 FDA Decisions To Watch in Q2 2026

6 FDA Decisions To Watch in Q2 2026

Published

on

The FDA has some big verdicts lined up in the second quarter, including one for a closely watched obesity drug that many anticipate will further intensify competition in weight loss.​ ​Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Replimune rebounds to win FDA approval of melanoma drug

The accelerated clearance follows two earlier rejections and the support of an advisory panel that disputed the arguments of FDA scientists.

Read More

Published

on

The accelerated clearance follows two earlier rejections and the support of an advisory panel that disputed the arguments of FDA scientists.

Read More

Continue Reading

Uncategorized

Third time’s the charm for Replimune as melanoma drug earns FDA greenlight

Third time’s the charm for Replimune as melanoma drug earns FDA greenlight

Published

on

Replimune’s immunotherapy for advanced melanoma faced a perilous regulatory road with two previous rejections, but the drug—to be marketed as Tudriqev—prevailed with strong support from oncologists and a 10-3 advisory committee vote in its favor.​ ​Read More

Continue Reading

Uncategorized

Tau and Alzheimer’s Disease

Published

on

Tau and</p><p>Alzheimer’s</p><p>Disease eBook cover” class=”wp-image-336117″/></figure></p><div class=

Continue Reading
Advertisement

Trending